The market for aesthetic medical devices gained some ground during the 2nd quarter, a MassDevice.com analysis shows, although healthy sales growth didn’t necessarily translate into healthy bottom lines for all comers.
Biolase
Mako Surgical details departure of senior marketing VP | Personnel Moves
Stryker to begin New York layoffs ahead of the medical device tax | Wall Street Beat
Heart pumps: Thoratec, HeartWare devices “basically equivalent” | Wall Street Beat
Bard transvaginal mesh lawsuits begin in February | Legal News
Australian J&J hip lawsuit attracts hundreds, may top $200M | Legal News
EU clears J&J’s $21B Synthes buyout | Wall Street Beat
Johnson & Johnson‘s (NYSE:JNJ) move to ditch its DePuy trauma business mollified EuroZone anti-trust regulators enough to win their approval for its $21.3 billion buyout of Synthes Inc.
Standard & Poor’s gives Medtronic an A+ | Wall Street Beat
Standard & Poor’s Ratings Services affirmed Medtronic’s (NYSE:MDT) long-term debt’s “A+” rating yesterday, after the med-tech titan announced another debt offering.
The rating agency said its view of Medtronic’s senior unsecured notes and its stable rating outlook “reflect the company’s ‘strong’ business risk profile and ‘modest’ financial risk profile.”
Biolase CEO Pignatelli touts $1 salary | Earnings Roundup
Biolase Technology (NSDQ:BLTI) CEO Federico Pignatelli agreed to another year at a $1 salary as the dental laser maker met Wall Street’s 4th-quarter forecast with a whopping 35% top-line bump.
Pignatelli set his annual pay package at $1 and 35,000 shares of BLTI stock when he took the role of vice chairman in July 2010, a month after he was terminated as president, SEC filings show.
Biolase CEO Pignatelli touts $1 salary
Biolase Technology (NSDQ:BLTI) CEO Federico Pignatelli agreed to another year at a $1 salary as the dental laser maker met Wall Street’s 4th-quarter forecast with a whopping 35% top-line bump.
Pignatelli set his annual pay package at $1 and 35,000 shares of BLTI stock when he took the role of vice chairman in July 2010, a month after he was terminated as president, SEC filings show.
Allezoe Medical says executive wrote affidavit for lawsuit opponent | Personnel Roundup
Allezoe Medical Holdings (OTC:ALZM) said board member and secretary Hyman White broke its internal rules and possibly state and federal laws when he wrote an affidavit supporting the un-named plaintiff in a lawsuit filed against Allezoe.